Poxel Names Decadt CEO to Drive Portfolio Growth and Asia Partnerships
Event summary
- Poxel appointed Yves Decadt as CEO on June 10, 2026, succeeding Nicolas Trouche, who led restructuring efforts since August 2025.
- Decadt, a former Johnson & Johnson executive, will focus on commercializing Imeglimin in China and Asia and developing PXL065 for hypertrophic cardiomyopathy and MASH.
- Poxel recently sold PXL770 to Scynexis as part of its Continuation Plan approved by the Lyon Commercial Court in January 2026.
The big picture
Poxel’s CEO transition marks a shift from restructuring to growth, with a focus on leveraging Decadt’s international business development experience. The company’s strategic pivot toward Asia and pipeline development aligns with broader trends in biopharma, where regional partnerships and specialized therapies are driving value creation. The sale of PXL770 to Scynexis provides financial flexibility, but the success of the Continuation Plan hinges on executing Decadt’s commercialization strategy.
What we're watching
- Asia Expansion
- How Decadt’s expertise in Asia will accelerate Imeglimin’s commercialization outside Japan.
- Pipeline Development
- The pace at which PXL065 advances through clinical trials for hypertrophic cardiomyopathy and MASH.
- Strategic Partnerships
- Whether Poxel can secure additional partnerships to monetize its portfolio beyond the Scynexis deal.
Related topics